泛PPAR激动剂拉尼兰诺治疗NASH的随机对照试验
这项2b期双盲随机安慰剂对照试验纳入247例非肝硬化高活动性NASH患者,按1:1:1接受拉尼兰诺1200mg、800mg或安慰剂每日一次共24周。主要终点为SAF-A评分下降≥2分且纤维化不恶化,1200mg组显著优于安慰剂(55% vs 33%,P=0.007),800mg组未达统计学显著(48% vs 33%,P=0.07)。
要点
- 拉尼兰诺1200mg可使SAF-A评分下降≥2分且纤维化不恶化比例显著高于安慰剂。
- 800mg组主要终点未达统计学显著,但NASH消退等次要终点两项剂量均优于安慰剂。
- 腹泻、恶心、外周水肿、贫血和体重增加在拉尼兰诺组更常见,因不良事件退出率低于5%。
核心结论
- 在活动性NASH患者中,拉尼兰诺1200mg组达到主要终点的比例显著高于安慰剂组。
- 结果支持拉尼兰诺进入3期临床试验进一步评估。
研究设计与样本
- 2b期、双盲、随机、安慰剂对照试验。
- 共247例非肝硬化高活动性NASH患者随机分配,按1:1:1接受拉尼兰诺1200mg、800mg或安慰剂每日一次治疗24周。
- 103例(42%)合并2型糖尿病,188例(76%)有显著(中度)或晚期纤维化。
主要发现
- 主要终点(SAF-A评分下降≥2分且纤维化不恶化):1200mg组55% vs 安慰剂33%,P=0.007;800mg组48% vs 33%,P=0.07。
- NASH消退且纤维化不恶化:1200mg组49%、800mg组39% vs 安慰剂22%。
- 纤维化分期改善≥1且NASH不恶化:1200mg组48%、800mg组34% vs 安慰剂29%。
- NASH消退且纤维化分期改善≥1:1200mg组35%、800mg组25% vs 安慰剂9%。
- 拉尼兰诺组肝酶水平下降,多数脂质、炎症和纤维化生物标志物改善。
关键数值与推荐
- SAF-A评分范围0至4分,评分越高表示疾病活动度越重。
- 主要终点定义为SAF-A评分下降至少2分且纤维化不恶化。
- 因不良事件退出率低于5%,各组相似。
- 腹泻、恶心、外周水肿、贫血和体重增加在拉尼兰诺组比安慰剂组更常见。
临床怎么用
- 拉尼兰诺1200mg每日一次可能改善高活动性NASH患者的疾病活动度且不恶化纤维化。
- 用药期间需关注腹泻、恶心、外周水肿、贫血和体重增加等不良反应。
- 目前证据来自2b期试验,尚需3期试验确认疗效与安全性后方可用于临床决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Management of nonalcoholic steatohepatitis (NASH) is an unmet clinical need. Lanifibranor is a pan-PPAR (peroxisome proliferator-activated receptor) agonist that modulates key metabolic, inflammatory, and fibrogenic pathways in the pathogenesis of NASH. METHODS: In this phase 2b, double-blind, randomized, placebo-controlled trial, patients with noncirrhotic, highly active NASH were randomly assigned in a 1:1:1 ratio to receive 1200 mg or 800 mg of lanifibranor or placebo once daily for 24 weeks. The primary end point was a decrease of at least 2 points in the SAF-A score (the activity part of the Steatosis, Activity, Fibrosis [SAF] scoring system that incorporates scores for ballooning and inflammation) without worsening of fibrosis; SAF-A scores range from 0 to 4, with higher scores indicating more-severe disease activity. Secondary end points included resolution of NASH and regression of fibrosis. RESULTS: A total of 247 patients underwent randomization, of whom 103 (42%) had type 2 diabetes mellitus and 188 (76%) had significant (moderate) or advanced fibrosis. The percentage of patients who had a decrease of at least 2 points in the SAF-A score without worsening of fibrosis was significantly higher among those who received the 1200-mg dose, but not among those who received the 800-mg dose, of lanifibranor than among those who received placebo (1200-mg dose vs. placebo, 55% vs. 33%, P = 0.007; 800-mg dose vs. placebo, 48% vs. 33%, P = 0.07). The results favored both the 1200-mg and 800-mg doses of lanifibranor over placebo for resolution of NASH without worsening of fibrosis (49% and 39%, respectively, vs. 22%), improvement in fibrosis stage of at least 1 without worsening of NASH (48% and 34%, respectively, vs. 29%), and resolution of NASH plus improvement in fibrosis stage of at least 1 (35% and 25%, respectively, vs. 9%). Liver enzyme levels decreased and the levels of the majority of lipid, inflammatory, and fibrosis biomarkers improved in the lanifibranor groups. The dropout rate for adverse events was less than 5% and was similar across the trial groups. Diarrhea, nausea, peripheral edema, anemia, and weight gain occurred more frequently with lanifibranor than with placebo. CONCLUSIONS: In this phase 2b trial involving patients with active NASH, the percentage of patients who had a decrease of at least 2 points in the SAF-A score without worsening of fibrosis was significantly higher with the 1200-mg dose of lanifibranor than with placebo. These findings support further assessment of lanifibranor in phase 3 trials. (Funded by Inventiva Pharma; NATIVE ClinicalTrials.gov number, NCT03008070.).
引用
- Francque SM, Bedossa P, Ratziu V, et al. A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH. N Engl J Med. 2021. PMID: 34670042. doi:10.1056/NEJMoa2036205
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。